Kevin Cheungandchristopher Yip News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Linklaters advises on HUTCHMED’s HK$4.17bn HKEX IPO
Linklaters advised the joint sponsors and underwriters on the global offering and listing of HUTCHMED (China) Limited (HUTCHMED) on the main board of the Hong Kong Stock Exchange (Stock Code: 13).
HUTCHMED, formerly known as Chi-Med (Hutchison China MediTech), is part of the multinational conglomerate CK Hutchison group. It is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialisation of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. It is the first biotech company to bring a novel oncology drug from discovery through to unconditional approval and launch in China. ....

Hong Kong , City Of , United Kingdom , Tiffany Yan , Christopher Yip , Kevin Cheungandchristopher Yip , China Limited , Hong Kong Stock Exchange Code , London Stock Exchange , Hong Kong Stock Exchange , Technology Innovation Board , Shanghai Stock Exchange Science , Stock Code , Hutchison China Meditech , American Depositary Shares , Nasdaq Global Select Market , London Stock , Technology Innovation , ஹாங் காங் , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , கிறிஸ்டோபர் இப் , சீனா வரையறுக்கப்பட்டவை , ஹாங் காங் ஸ்டாக் பரிமாற்றம் குறியீடு , லண்டன் ஸ்டாக் பரிமாற்றம் , ஹாங் காங் ஸ்டாக் பரிமாற்றம் ,